Federal Register Notice: FDA has determined the regulatory review period for Protalix Ltd.’s Elelyso (taliglucerase alfa) is 2,483 day for extending a patent which claims the human drug product. Elelyso is indicated for long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type 1 Gaucher disease. To view this notice, click here.
